Impact of Dexamethasone on Blood Glucose After Total Knee Arthroplasty in Patients With Type 2 Diabetes

Abstract

Objective: With the global aging population, the incidence of OA is rising annually, and the number of TKA surgeries is rapidly increasing, placing a heavy economic and healthcare burden on society. As one of the key medications in the ERAS protocol, DXM can significantly reduce postoperative pain, suppress nausea and vomiting, and accelerate patient recovery. However, the safety of perioperative DXM use in patients with diabetes remains unclear. This study aims to clarify the safety of perioperative DXM application in diabetic patients.

Methods: This retrospective analysis involved 285 patients with type 2 diabetes and late-stage knee osteoarthritis who underwent unilateral TKA at the Joint Surgery Center of Peking University Third Hospital from January 2019 to November 2022. After application of the inclusion and exclusion criteria, 161 patients were included in the study. The patients were divided into two groups according to whether they had received continuous intravenous administration of DXM for 3 days postoperatively: the DXM group (n = 66) and the non-DXM group (n = 95). All other treatments and medications were the same in both groups. The patients’ PBG, incidence of PONV, length of hospital stay, pain scores, and clinical data were collected and compared between the two groups.

Results: There were no significant differences in the general preoperative data between the DXM and non-DXM groups. The average PBG and the proportion of patients with levels exceeding 200 mg/dL were not significantly different between the two groups (10.84 mg/dL vs. 11.05 mg/dL and 43.2% vs. 43.9%). The postoperative visual analog scale scores (3.67 vs. 2.48) and the incidence of PONV were significantly lower in the DXM than non-DXM group (40% vs. 16%). The preoperative level of glycated hemoglobin accurately predicted PBG. Furthermore, there were no statistically significant differences in the incidence of early postoperative complications between the groups.

Conclusions: The administration of DXM after unilateral TKA can effectively reduce postoperative pain and suppress the occurrence of PONV without affecting PBG in patients with type 2 diabetes. In addition, the preoperative level of glycated hemoglobin can accurately predict PBG.

Keywords

dexamethasone / postoperative nausea and vomiting / total knee arthroplasty / type 2 diabetes

References

[1] S. Kurtz, K. Ong, E. Lau, F. Mowat, and M. Halpern, “Projections of Primary and Revision Hip and Knee Arthroplasty in the United States From 2005 to 2030,” Journal of Bone and Joint Surgery. American Volume 89, no. 4 (April 2007): 780–785.

[2] A. C. Brekke, E. J. Amaro, S. L. Posey, S. M. Engstrom, G. G. Polkowski, and J. G. Schoenecker, “Do Corticosteroids Attenuate the Peri-Operative Acute Phase Response After Total Knee Arthroplasty?,” Journal of Arthroplasty 34, no. 1 (January 2019): 27–35.

[3] C. Thongrong, P. Chullabodhi, P. Kasemsiri, et al., “Effects of Intraoperative Dexamethasone and Ondansetron on Postoperative Nausea and Vomiting in Microvascular Decompression Surgery: A Randomized Controlled Study,” Anesthesiology Research and Practice 2018 (2018): 1–5.

[4] G. Zhou, L. Ma, J. Jing, and H. Jiang, “A Meta-Analysis of Dexamethasone for Pain Management in Patients With Total Knee Arthroplasty,” Medicine (Baltimore) 97, no. 35 (August 2018): e11753.

[5] J. Hartman, V. Khanna, A. Habib, F. Farrokhyar, M. Memon, and A. Adili, “Perioperative Systemic Glucocorticoids in Total Hip and Knee Arthroplasty: A Systematic Review of Outcomes,” Journal of Orthopaedics 14, no. 2 (June 2017): 294–301.

[6] J. Vardy, K. S. Chiew, J. Galica, G. R. Pond, and I. F. Tannock, “Side Effects Associated With the Use of Dexamethasone for Prophylaxis of Delayed Emesis After Moderately Emetogenic Chemotherapy,” British Journal of Cancer 94, no. 7 (April 2006): 1011–1015.

[7] S. Liang, M. Xing, S. Jiang, and W. Zou, “Effect of Intravenous Dexamethasone on Postoperative Pain in Patients Undergoing Total Knee Arthroplasty: A Systematic Review and Meta-Analysis,” Pain Physician 25, no. 2 (March 2022): E169–e183.

[8] M. M. Harding, S. E. Xavier, T. M. Seyler, and S. P. Ryan, “The Effects of Dexamethasone in Diabetic Patients Undergoing Primary Total Joint Arthroplasty,” Orthopaedic Nursing 40, no. 5 (September-October 2021): 301–304.

[9] X. Wang, W. Jiang, Q. Huang, and F. Pei, “Dexamethasone Attenuates the Perioperative Acute Phase Response for Simultaneous Bilateral Total Hip Arthroplasty,” Journal of Arthroplasty 37, no. 5 (May 2022): 888–891.

[10] Y. Lei, Z. Huang, Q. Huang, F. Pei, and W. Huang, “Dose Optimization of Intravenous Dexamethasone for Total Knee Arthroplasty: When Two Is Not Better Than One,” Archives of Orthopaedic and Trauma Surgery 142, no. 4 (April 2022): 665–672.

[11] Y. T. Lei, B. Xu, X. W. Xie, J. W. Xie, Q. Huang, and F. X. Pei, “The Efficacy and Safety of Two Low-Dose Peri-Operative Dexamethasone on Pain and Recovery Following Total Hip Arthroplasty: A Randomized Controlled Trial,” International Orthopaedics 42, no. 3 (March 2018): 499–505.

[12] H. Xu, S. Zhang, J. Xie, Y. Lei, G. Cao, and F. Pei, “Multiple Doses of Perioperative Dexamethasone Further Improve Clinical Outcomes After Total Knee Arthroplasty: A Prospective, Randomized, Controlled Study,” Journal of Arthroplasty 33, no. 11 (November 2018): 3448–3454.

[13] M. Nurok, J. Cheng, G. R. Romeo, S. M. Vecino, K. G. Fields, and J. T. YaDeau, “Dexamethasone and Perioperative Blood Glucose in Patients Undergoing Total Joint Arthroplasty: A Retrospective Study,” Journal of Clinical Anesthesia 37 (February 2017): 116–122.

[14] L. S. Stryker, M. P. Abdel, M. E. Morrey, M. M. Morrow, D. J. Kor, and B. F. Morrey, “Elevated Postoperative Blood Glucose and Preoperative Hemoglobin A1C Are Associated With Increased Wound Complications Following Total Joint Arthroplasty,” Journal of Bone and Joint Surgery. American Volume 95, no. 9 (May 2013): 808–814.

[15] D. C. Allen, N. A. Jedrzynski, J. D. Michelson, M. Blankstein, and N. J. Nelms, “The Effect of Dexamethasone on Postoperative Blood Glucose in Patients With Type 2 Diabetes Mellitus Undergoing Total Joint Arthroplasty,” Journal of Arthroplasty 35, no. 3 (March 2020): 671–674.

[16] H. J. Park, M. J. Chang, T. W. Kim, K. S. Kang, C. B. Chang, and S. B. Kang, “Effects of Intravenous Dexamethasone on Glycemic Control in Patients With Type 2 Diabetes Mellitus After Total Knee Arthroplasty,” Journal of Arthroplasty 36, no. 12 (December 2021): 3909–3914.

[17] Y. Low, W. D. White, and A. S. Habib, “Postoperative Hyperglycemia After 4-Vs 8-10-Mg Dexamethasone for Postoperative Nausea and Vomiting Prophylaxis in Patients With Type II Diabetes Mellitus: A Retrospective Database Analysis,” Journal of Clinical Anesthesia 27, no. 7 (November 2015): 589–594.

[18] I. A. Jones, J. Wier, K. C. Liu, et al., “Dexamethasone-Associated Hyperglycemia Is Not Associated With Infectious Complications After Total Joint Arthroplasty in Diabetic Patients,” Journal of Arthroplasty 39 (August 2024): S43–S52.e5.

[19] F. Liu, M. Duan, H. Fu, and T. Wang, “The Efficacy and Safety of Perioperative Glucocorticoid for Total Knee Arthroplasty: A Systematic Review and Meta-Analysis,” BMC Anesthesiology 24, no. 1 (April 2024): 144.

[20] B. M. Godshaw, A. E. Mehl, J. G. Shaffer, M. S. Meyer, L. C. Thomas, and G. F. Chimento, “The Effects of Peri-Operative Dexamethasone on Patients Undergoing Total Hip or Knee Arthroplasty: Is It Safe for Diabetics?,” Journal of Arthroplasty 34, no. 4 (April 2019): 645–649.

[21] B. M. Godshaw, C. A. Ojard, T. M. Adams, G. F. Chimento, A. Mohammed, and B. S. Waddell, “Preoperative Glycemic Control Predicts Perioperative Serum Glucose Levels in Patients Undergoing Total Joint Arthroplasty,” Journal of Arthroplasty 33, no. 7s (July 2018): S76–s80.

[22] J. R. Backes, J. C. Bentley, J. R. Politi, and B. T. Chambers, “Dexamethasone Reduces Length of Hospitalization and Improves Postoperative Pain and Nausea After Total Joint Arthroplasty: A Prospective, Randomized Controlled Trial,” Journal of Arthroplasty 28, no. 8 Suppl (September 2013): 11–17.

[23] M. Tarabichi, N. Shohat, M. M. Kheir, et al., “Determining the Threshold for HbA1c as a Predictor for Adverse Outcomes After Total Joint Arthroplasty: A Multicenter, Retrospective Study,” Journal of Arthroplasty 32, no. 9s (September 2017): S263–S267.e1.

[24] A. H. Harris, T. R. Bowe, S. Gupta, L. S. Ellerbe, and N. J. Giori, “Hemoglobin A1C as a Marker for Surgical Risk in Diabetic Patients Undergoing Total Joint Arthroplasty,” Journal of Arthroplasty 28, no. 8 Suppl (September 2013): 25–29.

[25] X. Liu, J. Liu, and G. Sun, “Preoperative Intravenous Glucocorticoids Can Reduce Postoperative Acute Pain Following Total Knee Arthroplasty: A Meta-Analysis,” Medicine 96 (2017): e7836.

[26] N. Tammachote and S. Kanitnate, “Intravenous Dexamethasone Injection Reduces Pain From 12 to 21 Hours After Total Knee Arthroplasty: A Double-Blind, Randomized, Placebo-Controlled Trial,” Journal of Arthroplasty 35, no. 2 (2020): 394–400.

[27] B. Mraovic, D. Suh, C. Jacovides, and J. Parvizi, “Perioperative Hyperglycemia and Postoperative Infection After Lower Limb Arthroplasty,” Journal of Diabetes Science and Technology 5, no. 2 (2011): 412–418.

[28] R. Iorio, K. M. Williams, A. J. Marcantonio, L. M. Specht, J. F. Tilzey, and W. L. Healy, “Diabetes Mellitus, Hemoglobin A1C, and the Incidence of Total Joint Arthroplasty Infection,” Journal of Arthroplasty 27, no. 5 (2012): 726–729.e721.

[29] S. K. Chia, G. C. Wernecke, I. A. Harris, M. T. Bohm, D. B. Chen, and S. J. Macdessi, “Peri-Articular Steroid Injection in Total Knee Arthroplasty: A Prospective, Double Blinded, Randomized Controlled Trial,” Journal of Arthroplasty 28, no. 4 (April 2013): 620–623.

[30] A. V. Papavasiliou, D. L. Isaac, R. Marimuthu, A. Skyrme, and A. Armitage, “Infection in Knee Replacements After Previous Injection of Intra-Articular Steroid,” Journal of Bone and Joint Surgery. British Volume (London) 88, no. 3 (March 2006): 321–323.

[31] A. Mullaji, R. Kanna, G. M. Shetty, and V. Chavda, “Efficacy of Periarticular Injection of Bupivacaine, Fentanyl, and Methylprednisolone in Total Knee Arthroplasty: A Prospective, Randomized Trial,” Journal of Arthroplasty 25, no. 6 (2010): 851–857.

[32] D. Li, J. Zhao, Z. Yang, P. Kang, B. Shen, and F. Pei, “Multiple Low Doses of Intravenous Corticosteroids to Improve Early Rehabilitation in Total Knee Arthroplasty: A Randomized Clinical Trial,” Journal of Knee Surgery 32, no. 2 (February 2019): 171–179.

[33] N. I. Nielsen, H. Kehlet, K. Gromov, et al., “High-Dose Steroids in High Pain Responders Undergoing Total Knee Arthroplasty: A Randomised Double-Blind Trial,” British Journal of Anaesthesia 128 (2022): 150–158.

RIGHTS & PERMISSIONS

2025 The Author(s). Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.